This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

Pd-L1 Testing Based on The SP142 Antibody in Metastatic Triple-Negative Breast Cancer: Summary of an Expert Round-Table Discussion

Volume: 17, Issue: 10, Pages: 1209 - 1218
Published: Dec 8, 2020
Abstract
Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays...
Paper Details
Title
Pd-L1 Testing Based on The SP142 Antibody in Metastatic Triple-Negative Breast Cancer: Summary of an Expert Round-Table Discussion
Published Date
Dec 8, 2020
Volume
17
Issue
10
Pages
1209 - 1218
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.